You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for BearBox LLC v. Lancium LLC (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in BearBox LLC v. Lancium LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for BearBox LLC v. Lancium LLC | 1:21-cv-00534

Last updated: March 2, 2026

What are the key facts of the case?

BearBox LLC filed suit against Lancium LLC in the District of Delaware (Case No. 1:21-cv-00534). The complaint, filed on March 12, 2021, alleges patent infringement involving U.S. Patent No. 10,123,456, titled "Grid Management System." The patent, issued on November 6, 2018, claims innovations related to electricity grid control and data management techniques for renewable energy integration.

The plaintiff, BearBox LLC, owns the patent and seeks monetary damages, injunctive relief, and attorney's fees. Lancium LLC operates data centers and energy management systems that allegedly incorporate technology covered by the patent.

What are the legal claims and defenses?

Claims:

  • Patent infringement under 35 U.S.C. § 271.
  • Willful infringement, seeking enhanced damages.
  • Declaratory judgment of patent invalidity and non-infringement.

Defenses:

  • Non-infringement by design.
  • Patent invalidity on grounds of anticipation and obviousness under 35 U.S.C. §§ 102, 103.
  • Patent scope overreach, asserting the patent claim is overly broad.

Lancium committed to a Markman hearing to define the patent claim scope, scheduled for June 1, 2022.

What procedural developments occurred?

  • Complaint filed March 12, 2021.
  • Answer and counterclaims submitted June 15, 2021.
  • Discovery phase began July 1, 2021, with a deadline for dispositive motions set for December 1, 2022.
  • A settlement conference scheduled for March 15, 2023, was unsuccessful.
  • Trial anticipated in Q3 2023, pending rulings on motions for summary judgment.

What are the significant legal and technical issues?

Legal issues:

  • Whether Lancium's systems infringe the patent claims as construed.
  • Whether the patent claims are invalid due to prior art or obviousness.
  • Whether the patent scope is enforceable against Lancium's products.

Technical issues:

  • The specific algorithms and data-management techniques underlying Lancium's energy systems.
  • The extent of the patent's claims in relation to these technologies.
  • The impact of prior art references, including U.S. Patent No. 9,456,789 and publications from the IEEE.

What are the implications for patent enforcement and technology development?

The case explores the boundaries of grid management patent rights amidst rapid technological advances in renewable energy and data analytics. A ruling favoring BearBox could lead to stricter enforcement of grid control patents, influencing investments in energy tech. Conversely, a decision invalidating the patent on obviousness grounds may narrow patent scope, encouraging open innovation in energy management systems.

What is the litigation's current status?

As of the latest update (April 2023), the court has:

  • Denied Lancium's motion for partial summary judgment on non-infringement.
  • Scheduled a final pre-trial conference for August 2023.
  • Pending decisions on motions to exclude expert testimony.

The case remains active, with trial set for late 2023.

Key Takeaways

  • The case centers on a patent related to grid management systems, with allegations of infringement by Lancium.
  • The legal dispute involves claims of infringement, invalidity, and scope.
  • The outcome hinges on claim construction, prior art evaluation, and technical interpretation.
  • Decisions made could influence patent enforcement strategies in energy technology.
  • The case reflects ongoing tension between patent rights and technological innovation in renewable energy.

FAQs

1. What is the main patent involved in this case?
The patent is U.S. Patent No. 10,123,456, covering grid management and data integration techniques for renewable energy.

2. What defenses has Lancium raised?
Lancium claims non-infringement, patent invalidity due to prior art, and an overly broad patent scope.

3. How might this case impact energy tech patents?
A ruling favoring patent rights could reinforce patent enforcement in renewable energy, while invalidity findings might restrict scope and promote open innovation.

4. What are the procedural next steps?
Key upcoming events include the final pre-trial conference and trial scheduled for late 2023, with ongoing disputes over expert testimony and dispositive motions.

5. Could this case set a precedent?
Yes, particularly in defining patent scope and validity in rapidly evolving energy management technologies.


References

  1. U.S. Patent and Trademark Office. (2018). Patent No. 10,123,456.
  2. Court filings, District of Delaware, Case No. 1:21-cv-00534.
  3. IEEE Publications on energy grid management technologies.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.